Investors

2023

OptiBiotix Health plc ("OptiBiotix") announces that Graham Myers, Finance Director of the Company, has notified the Company that he will step down from the Board on 30 November 2024.

David Blain will join the Company as acting Finance Director on 1 November 2024. Mr Blain's appointment to the Board of the Company will be subject to normal regulatory due diligence.

David is a member of ICAEW and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.

The Company notes recent speculation in relation to the health of the Company's Chief Executive Officer Stephen O'Hara.  Mr O'Hara is recovering after a short illness and expects to be back at work shortly.

Neil Davidson, Chairman of OptiBiotix Health plc said: "On behalf of the Board, I would like to thank Graham for his contribution to the Company over the last year and welcome David as we move to our next stage of growth."

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2022

OptiBiotix Health plc ("OptiBiotix") announces that Graham Myers, Finance Director of the Company, has notified the Company that he will step down from the Board on 30 November 2024.

David Blain will join the Company as acting Finance Director on 1 November 2024. Mr Blain's appointment to the Board of the Company will be subject to normal regulatory due diligence.

David is a member of ICAEW and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.

The Company notes recent speculation in relation to the health of the Company's Chief Executive Officer Stephen O'Hara.  Mr O'Hara is recovering after a short illness and expects to be back at work shortly.

Neil Davidson, Chairman of OptiBiotix Health plc said: "On behalf of the Board, I would like to thank Graham for his contribution to the Company over the last year and welcome David as we move to our next stage of growth."

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2021

OptiBiotix Health plc ("OptiBiotix") announces that Graham Myers, Finance Director of the Company, has notified the Company that he will step down from the Board on 30 November 2024.

David Blain will join the Company as acting Finance Director on 1 November 2024. Mr Blain's appointment to the Board of the Company will be subject to normal regulatory due diligence.

David is a member of ICAEW and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.

The Company notes recent speculation in relation to the health of the Company's Chief Executive Officer Stephen O'Hara.  Mr O'Hara is recovering after a short illness and expects to be back at work shortly.

Neil Davidson, Chairman of OptiBiotix Health plc said: "On behalf of the Board, I would like to thank Graham for his contribution to the Company over the last year and welcome David as we move to our next stage of growth."

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2020

OptiBiotix Health plc ("OptiBiotix") announces that Graham Myers, Finance Director of the Company, has notified the Company that he will step down from the Board on 30 November 2024.

David Blain will join the Company as acting Finance Director on 1 November 2024. Mr Blain's appointment to the Board of the Company will be subject to normal regulatory due diligence.

David is a member of ICAEW and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.

The Company notes recent speculation in relation to the health of the Company's Chief Executive Officer Stephen O'Hara.  Mr O'Hara is recovering after a short illness and expects to be back at work shortly.

Neil Davidson, Chairman of OptiBiotix Health plc said: "On behalf of the Board, I would like to thank Graham for his contribution to the Company over the last year and welcome David as we move to our next stage of growth."

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2019

OptiBiotix Health plc ("OptiBiotix") announces that Graham Myers, Finance Director of the Company, has notified the Company that he will step down from the Board on 30 November 2024.

David Blain will join the Company as acting Finance Director on 1 November 2024. Mr Blain's appointment to the Board of the Company will be subject to normal regulatory due diligence.

David is a member of ICAEW and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.

The Company notes recent speculation in relation to the health of the Company's Chief Executive Officer Stephen O'Hara.  Mr O'Hara is recovering after a short illness and expects to be back at work shortly.

Neil Davidson, Chairman of OptiBiotix Health plc said: "On behalf of the Board, I would like to thank Graham for his contribution to the Company over the last year and welcome David as we move to our next stage of growth."

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 

2018

OptiBiotix Health plc ("OptiBiotix") announces that Graham Myers, Finance Director of the Company, has notified the Company that he will step down from the Board on 30 November 2024.

David Blain will join the Company as acting Finance Director on 1 November 2024. Mr Blain's appointment to the Board of the Company will be subject to normal regulatory due diligence.

David is a member of ICAEW and has extensive financial, commercial and Board experience in a number of private and public companies, including Iksuda Therapeutics Ltd, Applied Graphene Materials plc, Nanoco Group plc and Inspired Capital plc (formerly Renovo Group plc). Mr Blain is currently Financial Director (non-board position) at Iksuda Therapeutics Ltd.

The Company notes recent speculation in relation to the health of the Company's Chief Executive Officer Stephen O'Hara.  Mr O'Hara is recovering after a short illness and expects to be back at work shortly.

Neil Davidson, Chairman of OptiBiotix Health plc said: "On behalf of the Board, I would like to thank Graham for his contribution to the Company over the last year and welcome David as we move to our next stage of growth."

About OptiBiotix - www.optibiotix.com

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.

OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.

OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.